Connect with us

Hi, what are you looking for?

Saturday, Nov 26, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Numinus approved to study ayahuasca and San Pedro in Canada

Used in sacred traditions for centuries, the firm says research will bring their medicinal benefits to a larger audience

Numinus approved to study two natural psychedelics used by Indigenous groups for centuries
San Pedro or Echynopsis pachanoi is a cactus used and considered sacred by pre-Colombian cultures such as Chavin, Mochica, Ware and Quechua in South America. Photo by Cbrescia via Wikimedia Commons

Psychedelics company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has received approval from Health Canada to conduct research on an ancestral South American psychedelic brew, and a cactus used for centuries by pre-Columbian Indigenous groups.

On Wednesday, the Vancouver-based company said it received approval from Health Canada to study the DMT-containing brew ayahuasca, and the cactus San Pedro, which contains mescaline.

Specifically, the company’s research branch Numinus Biosciences will be studying the alkaloid-rich plants used to make ayahuasca, including caapi, chacruna, chagropanga and jurema preta.

Caapi contains harmaline and harmalol, which are alkaloids that work with the other DMT-containing plants to produce a stronger and longer psychedelic experience.

Ayahuasca is a psychedelic concoction produced by mixing leaves and bark from the plants. It’s traditionally consumed for ceremonial, medicinal and spiritual purposes by Amazonian Indigenous groups, but it has become popular among Westerners for its strong psychedelic effects and mental health benefits.

San Pedro is a cactus considered sacred by cultures such as Chavin, Mochica, Ware and Quechua in South America. It contains mescaline, which is also found in other cacti like peyote and Peruvian torches. The cacti can be dried and consumed as a dry powder or drank in a brew.

The company will develop standardized analytical methods for both psychedelics to be used in research.

Numinus approved to study two psychedelic plants used in South American Indigenous traditions

Photo by Apollo via Wikimedia Commons

Read more: Numinus ups revenue 61% thanks to psychedelic-focused therapy programs

Read more: Numinus submits novel psilocybe formulation for clinical trial

Science officer at Numinus Bioscience Sharan Sidhu says there’s little research on the plants, and the company is broadening its research on naturally ocurring ethnobotanical substances, their mixtures and synergies.

“This is a first step in helping us better understand their mechanisms and potential therapeutic applications,” Sidhu says.

The company has licences to study, possess, test, produce, sell and export DMT, ketamine, LSD, MDMA, mescaline, psilocin and psilocybin.

“Many naturally occurring psychedelic compounds have already been in traditional use for millennia,” CEO Payton Nyquvest says.

“These amendments honour and build on those practices while allowing us to do novel clinical research and deepen the body of scientific data for scaled development and greater public access to much-needed therapies.”


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Natalia Buendia Calvillo on Twitter

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The bill would reduce 'unreasonably burdensome rules and regulations'


The trial is the first psilocybin study funded by the Canadian Institutes of Health Research (CIHR)


The companies say this will be the 'world's first' in-clinic application of VR with psychedelic-assisted therapy


New phase I study will be held at MAC Clinical Research in Manchester, England next year